Tibolone: A steroid with a tissue-specific mode of action

Journal of Steroid Biochemistry and Molecular Biology

Volumn 76, Issue 1-5, 2001, Pages 231-238

  Kloosterboer, H J ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Bone; Breast; Cardiovascular system; Climacterium; Endometrium; Inhibition; Steroid metabolism; Steroid receptors; Sulphatase; Tibolone

Indexed keywords

11BETA [4 (DIMETHYLAMINO)PHENYL] 4',5' DIHYDRO 6BETA METHYLSPIRO[ESTRA 4,9 DIENE 17BETA,2'(3'H) FURAN] 3 ONE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTIESTROGEN; ANTIGESTAGEN; DIMETHYLBENZ[A]ANTHRACENE; DRUG METABOLITE; ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; FLUTAMIDE; HYDROXYL GROUP; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; STEROID; SULFATASE; TAMOXIFEN; TIBOLONE;

APOPTOSIS; BONE ATROPHY; BONE MASS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CLIMACTERIUM; CONFERENCE PAPER; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENDOMETRIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; POSTMENOPAUSE; RECEPTOR AFFINITY; SKIN TEMPERATURE; VAGINA ATROPHY;

ANABOLIC AGENTS; CLIMACTERIC; KINETICS; NORPREGNENES; OSTEOPOROSIS;

EID: 0034987346     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00044-9     Document Type: Conference Paper

References (56)

1. Pharmacological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD14)
2. Endocrinological studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD14)
3. At the cutting edge: Intracinology
4. Nuclear receptor coregulators: Cellular and molecular biology
5. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium
6. Metabolism of three pharmacologically active drugs in isolated human and rat hepatocytes: Analysis of interspecies variability and comparison with metabolism in vivo
7. Pharmacokinetics of estradiol, free and total estrone in young women following single intravenous and oral administration of 17β-estradiol
8. Enterohepatic cycling and pharmacokinetics of oestradiol in postmenopausal women
9. Bioequivalence assessment of three different estradiol formulations in postmenopausal women in an open, randomized, single dose, 3-way cross-over study
10. Pharmacology and pharmacokinetics of estrogens
11. 3H] norethynodrel in the human endometrium and the myometrium
12. Metabolism of antifertility steroids. I. Norethynodrel
13. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens
14. Sulphated metabolites of tibolone show sulphatase inhibiting activity
15. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD14)
16. Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivates
17. Tibolone: Prevention of bone loss in late postmenopausal women
18. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women
19. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: A two-year randomized placebo-controlled study
20. An assessment of hormone replacement therapy to prevent postmenopausal osteoporosis
21. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
22. Alendronate treatment for osteoporosis: A review of the clinical evidence
23. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rat
24. Tibolone exerts an estrogenic effect on bone leading to prevention of bone loss and reduction in bone resorption in ovariectomized rats
25. A sixteen month treatment with tibolone prevents loss of bone and maintains biomechanical quality of cortical and trabecular bone in ovariectomized rats
26. Tibolone a review
27. The effects of tibolone
28. A primate model of human postmenopausal hot flushes
29. Effect of tibolone in two animal models for menopausal hot flushes
30. Effects of Org OD14 on pituitary and peripheral beta-endorphin in castrated rats and postmenopausal women
31. Effects of Org OD14 on pituitary and peripheral β endorphin in castrated rats and postmenopausal women
32. The use of androgens in menopause
33. A key enzyme in the biosynthesis of neurosteroids, 3β-hydroxysterid dehydrogenase/Δ5-Δ4-isomerase (3β-HSD), is expressed in rat brain
34. 3β-Hydroxysteroid dehydrogenase activity in tissues of human fetus determined with 5a-androstane-3β, 17β-diol and dehydroepiandrosterone as substrates
35. Organon OD14 (tibolone) and menopausal dynamic hormone profiles
36. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD14) and its metabolites on human endometrium
37. On behalf of the collaborative group on hormonal factors in breast cancer
38. Effect of progestagens and Org OD14 in in vitro and in vivo tumor models
39. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells
40. Concentration of estrone, estradiol, estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients
41. Inhibition of estrone sulfatase activity by estrone-3-0-methylthiophosphonate: A potential therapeutic agent in breast cancer
42. Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells
43. Effects of Org OD14 (Livial®) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells
44. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy
45. Tibolone inhibits sulfatase activity in breast but not in bone
46. Tibolone: A tissue-specific sulphatase inhibitor
47. Inhibition of oestrone sulphatase activity by tibolone (Org OD14) and its metabolites
48. Effects of postmenopausal oestrongen-progestagen replacement therapy on serum lipids and lipoproteins: A review
49. Tibolone: Influence on markers of cardiovascular disease
50. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with cyclical estrogen/progestagen regimen
51. Lowered HDL cholesterol and incidence of ischaemic heart disease
52. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women
53. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clothing cascade: A multicenter, double-blind, randomized study
54. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women
55. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits
56. Tibolone inhibits leucocyte adhesion molecule expression in human endothelial cells